Nwam LLC Sells 39,812 Shares of Insmed, Inc. $INSM

Nwam LLC decreased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 88.7% in the 2nd quarter, Holdings Channel reports. The firm owned 5,071 shares of the biopharmaceutical company’s stock after selling 39,812 shares during the period. Nwam LLC’s holdings in Insmed were worth $541,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Reflection Asset Management bought a new stake in Insmed during the fourth quarter valued at approximately $30,000. CIBC Private Wealth Group LLC increased its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. Raiffeisen Bank International AG bought a new position in shares of Insmed in the 4th quarter worth $32,000. Larson Financial Group LLC raised its position in shares of Insmed by 137.0% during the 4th quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 148 shares in the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new stake in shares of Insmed during the 4th quarter valued at $49,000.

Insider Activity at Insmed

In other news, insider Michael Smith sold 1,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total transaction of $173,050.92. Following the completion of the sale, the insider owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. This represents a 70.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 273,753 shares of company stock worth $35,604,764 in the last ninety days. 2.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on INSM. Evercore reiterated an “outperform” rating and issued a $170.00 target price on shares of Insmed in a research report on Friday, August 7th. UBS Group restated a “buy” rating and set a $172.00 price target on shares of Insmed in a research report on Friday, August 7th. Truist Financial reaffirmed a “buy” rating and set a $195.00 price target (up from $185.00) on shares of Insmed in a research note on Monday, August 10th. Jefferies Financial Group reiterated a “buy” rating and issued a $175.00 price objective on shares of Insmed in a report on Thursday, August 6th. Finally, Royal Bank Of Canada decreased their price objective on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $205.52.

Insmed Stock Performance

Insmed stock opened at $126.68 on Friday. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $27.66 billion, a PE ratio of -30.82 and a beta of 0.82. The firm has a fifty day simple moving average of $115.40 and a two-hundred day simple moving average of $125.21. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. The firm had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The company’s revenue for the quarter was up 296.1% compared to the same quarter last year. During the same period last year, the firm earned ($1.70) earnings per share. Research analysts expect that Insmed, Inc. will post -1.83 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.